A5026641386- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Viral-associated cancers and disorders
- CNS Lymphoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Immune Cell Function and Interaction
- Lung Cancer Treatments and Mutations
- Acute Lymphoblastic Leukemia research
- Cutaneous lymphoproliferative disorders research
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Epigenetics and DNA Methylation
- T-cell and Retrovirus Studies
- Chronic Myeloid Leukemia Treatments
- Ovarian cancer diagnosis and treatment
- Radiomics and Machine Learning in Medical Imaging
- Genetic factors in colorectal cancer
- Multiple and Secondary Primary Cancers
- HER2/EGFR in Cancer Research
- Ubiquitin and proteasome pathways
- Medical Imaging Techniques and Applications
- Sarcoma Diagnosis and Treatment
- Glioma Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
Spinal Cord Injury BC
2014-2025
University of British Columbia
2016-2025
BC Cancer Agency
2015-2024
Mansoura University Hospital
2023
Washington University in St. Louis
2023
Provincial Health Services Authority
2019-2022
Georgetown University
2018
Charles University
2018
Istituti di Ricovero e Cura a Carattere Scientifico
2017
Centre for Sight
2017
Since the publication of Revised European-American Classification Lymphoid Neoplasms in 1994, subsequent updates classification lymphoid neoplasms have been generated through iterative international efforts to achieve broad consensus among hematopathologists, geneticists, molecular scientists, and clinicians. Significant progress has recently made characterization malignancies immune system, with many new insights provided by genomic studies. They led this proposal. We followed same process...
For more than two decades, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has been the standard therapy for diffuse large B-cell lymphoma (DLBCL). The addition of rituximab to CHOP shown improve outcome in elderly patients with DLBCL. We conducted a population-based analysis assess impact this combination on adult DLBCL province British Columbia (BC).We compared outcomes during 3-year period; 18 months before (prerituximab) after (postrituximab) institution policy...
Purpose Diffuse large B-cell lymphoma (DLBCL) is curable in 60% of patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). MYC translocations, or without BCL2 have been associated inferior survival DLBCL. We investigated whether expression protein, protein expression, could risk-stratify at diagnosis. Patients Methods determined the correlation between presence proteins by immunohistochemistry (IHC) two independent cohorts DLBCL R-CHOP....
Patients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) fare poorly, limited treatment options. The antibody-drug conjugate polatuzumab vedotin targets CD79b, a receptor component.Safety and efficacy of bendamustine obinutuzumab (pola-BG) was evaluated in single-arm cohort. Polatuzumab combined rituximab (pola-BR) compared (BR) randomly assigned cohort patients R/R DLBCL (primary end point: independent review committee [IRC] assessed complete...
Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60% of patients are cured R-CHOP. Polatuzumab vedotin an antibody-drug conjugate targeting CD79b, which ubiquitously expressed on the surface malignant B cells.We conducted a double-blind, placebo-controlled, international phase 3 trial to evaluate modified regimen R-CHOP (pola-R-CHP), in vincristine was replaced polatuzumab vedotin, as...
PURPOSE Ibrutinib has shown activity in non–germinal center B-cell diffuse large lymphoma (DLBCL). This double-blind phase III study evaluated ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) untreated DLBCL. PATIENTS AND METHODS Patients were randomly assigned at a one-to-one ratio to (560 mg per day orally) R-CHOP or placebo R-CHOP. The primary end point was event-free survival (EFS) the intent-to-treat (ITT) population activated (ABC) DLBCL...
A number of novel therapies are under investigation in relapsed or refractory peripheral T-cell lymphoma (PTCL); however, their relative impact on outcome is unknown. We examined the survival patients with PTCL after relapse progression absence hematopoietic stem-cell transplantation and explored factors influencing survival. The three most common subtypes encountered North America were evaluated: not otherwise specified (PTCL-NOS), angioimmunoblastic (AITL), anaplastic large-cell (ALCL;...
To develop and validate a risk score for relapse in the CNS patients with diffuse large B-cell lymphoma (DLBCL).A total of 2,164 (18 to 80 years old) aggressive lymphomas (80% DLBCL) treated rituximab CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)-like chemotherapy, who were enrolled studies from German High-Grade Non-Hodgkin Lymphoma Study Group MabThera International Trial, analyzed occurrence relapse/progression CNS. The resulting model was validated an independent data set...
Purpose Rituximab (R) plus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy is the standard of care in previously untreated diffuse large B-cell lymphoma (DLBCL). Obinutuzumab (G) a glycoengineered, type II, anti-CD20 monoclonal antibody. GOYA was randomized phase III study that compared G-CHOP with R-CHOP patients advanced-stage DLBCL. Methods Patients (N = 1,418) were randomly assigned to receive eight 21-day cycles G (n 706) or R 712), six CHOP. Primary end point...
To evaluate the prognostic impact of cell-of-origin (COO) subgroups, assigned using recently described gene expression-based Lymph2Cx assay in comparison with International Prognostic Index (IPI) score and MYC/BCL2 coexpression status (dual expressers).Reproducibility COO assignment was tested employing repeated sampling within tumor biopsies changes reagent lots. The then applied to pretreatment formalin-fixed paraffin-embedded tissue (FFPET) from 344 patients de novo diffuse large B-cell...
To assess the incidence and predictive factors for development of transformed lymphoma in a population-based series patients with follicular (FL).The Lymphoid Cancer Database was used to identify FL diagnosed treated province British Columbia, Canada. Transformed defined as aggressive non-Hodgkin's (NHL) FL. Factors present at time initial diagnosis indolent NHL transformation were analyzed their impact on risk subsequent outcome.Between 1986 2001, 600 newly met inclusion criteria. With...
High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH) has a poor outcome after standard chemoimmunotherapy. We sought to understand the biologic underpinnings of HGBL-DH/TH (HGBL-DH/TH- BCL2) diffuse large (DLBCL) morphology through examination gene expression.We analyzed RNA sequencing data from 157 de novo germinal center B-cell-like (GCB)-DLBCLs, including 25 HGBL-DH/TH- BCL2, define expression signature that distinguishes other GCB-DLBCLs. To assess...
Rituximab plus chemotherapy has been shown to be effective in patients with advanced-stage, previously untreated follicular lymphoma; nevertheless, most will have a relapse. Combination immunotherapy lenalidomide and rituximab is an immunomodulatory regimen that promising activity indolent B-cell non-Hodgkin's lymphoma.